Mark Hurtt, M.D., Acting Chief Medical Officer

Oct. 11 | 9:45am | Ecolab Life Sciences Ballroom 

Wakefield, MA


Myrtelle Inc. is a gene therapy company focused on developing transformative treatments for neurodegenerative diseases. The company has a proprietary platform, intellectual property, and portfolio of programs and technologies supporting innovative gene therapy approaches for neurodegenerative diseases. Myrtelle has an exclusive worldwide licensing agreement with Pfizer Inc. for its lead program in Canavan disease. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions